Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives

Drug Discov Today. 2015 Mar;20(3):332-46. doi: 10.1016/j.drudis.2014.10.007. Epub 2014 Oct 31.

Abstract

Diabetic nephropathy (DN) is one of the most common complications of diabetes with high mortality rates worldwide. The treatment of DN has posed a formidable challenge to the scientific community. Simple control of risk factors has been insufficient to cope with the progression of DN. During the process of anti-DN drug discovery, multiple pathogeneses such as oxidative stress, inflammation and fibrosis should all be considered. In this review, the pathogenesis of DN is summarized. The major context focuses on a few small molecules toward the pathogenesis available in animal models and clinical trials for the treatment of DN. The perspectives of novel anti-DN agents and the future directions for the prevention of DN are discussed.

Publication types

  • Review

MeSH terms

  • Animals
  • Diabetic Nephropathies / drug therapy*
  • Diabetic Nephropathies / metabolism
  • Drug Discovery*
  • Fibrosis / drug therapy
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use*
  • Inflammation / drug therapy
  • Protein Kinase C beta / metabolism
  • Risk Factors

Substances

  • Hypoglycemic Agents
  • Protein Kinase C beta